Shots:
- Ocugen has licensed exclusive MENA rights for OCU400, its modifier gene therapy for retinitis pigmentosa, to Roots Pharmaceutical & its strategic partner Al-Dhow International Holding
- As per the deal, Ocugen will receive ~$4M in upfront fee & development milestones, plus ~$255M in sales milestones, & royalties equaling 22% of OCU400 net sales by Roots Pharmaceutical
- Ocugen will manufacture OCU400’s commercial supply under a separate agreement, while advancing its P-III (liMeliGhT) trial, with topline results readout expected in Q1’27, followed by planned US BLA and European MAA submissions
Ref: Globenewswire | Image: Ocugen & Roots Pharmaceutical | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
